Navigation Links
Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
Date:9/6/2007

KNOXVILLE, TN--Provectus Pharmaceuticals, Inc. (OTCBB:PVCT) announced that it has obtained approval to begin Phase 2 clinical testing of Provecta for the treatment of Stage III and IV metastatic melanoma, the most aggressive and deadly form of skin cancer. The multi-center study is designed to evaluate efficacy of Provecta in a total of 80 subjects.

In the study, Provecta will be injected into up to 20 tumors in each subject. Additional treatment with Provecta may be made 8 to 16 weeks after this initial injection, if deemed necessary by the investigator. Response will be observed for 1 year, during which data will be gathered for assessment of objective response rate, progression free survival, quality of life and safety. In addition, CT imaging will be used to monitor changes in any internal (e.g., visceral or brain) metastases. The lead site for the study is the Sydney Melanoma Unit in Australia. Over the next several months the study will expand to include sites in a number of major population centers in Australia as well as several sites in the U.S.

Craig Dees, Ph.D., Chief Executive Officer of Provectus, stated, Building on the results from our Phase 1 study, which looked at safety and objective response upon injection of Provecta into more than 100 metastatic melanoma tumors in 20 subjects, we have put forth an aggressive clinical plan to drive toward approval of the drug for use in this devastating disease. Dees continued, Preliminary analysis of data from Phase 1 shows that Provecta, which has received orphan drug designation in the U.S., was well tolerated with generally mild side effects. Having completed final follow-up for the last of these subjects, we expect to announce summary response data in the near future.


'/>"/>
Contact: Janet Vasquez
janet@investorrelationsgroup.com
212-825-3210
Provectus Pharmaceuticals
Source:Eurekalert

Page: 1

Related medicine news :

1. Risk of heart disease begins in teens
2. Cancer Begins With Epigenetic Changes: Study
3. Learning About Healthy Diet Choices Begins At Schools
4. China Begins Human Trials For HIV/AIDS Drug
5. Administration of Fish Drug for Asthma Patients Begins in Andhra
6. Harvard Begins Controversial Human Stem Cell Cloning Project
7. Writing on the Wall - Lead Poisoning Begins at Home?Paints Could Be Toxic!
8. The Blessing of Good Mental Health Begins with Breast Milk, Says a Study
9. India sounds bird flu alert as migration season begins
10. Keys to Good Health in Old Age Begins in Midlife
11. Cancer Prevention Begins During Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Parker Waichman LLP, a personal injury ... that the heroes of 9/11 are never forgotten, comments that ... important deadline. According to a VCF message dated ... cancer on or before October 12, 2012 must file a ... and others who were allegedly injured by the toxic dust ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... relieve sleep apnea in children, but a new study confirms ... if they,re already overweight. The researchers said that,s a ... of health problems -- including, ironically, sleep apnea. But they,re ... Instead, they said, doctors and parents should be aware that ...
(Date:7/28/2014)... Sarasota-based FCCI Insurance Group (FCCI) was recently ... Still headquartered in Sarasota where it was originally founded ... the top ten of the Best Large Companies category. ... August issue of Florida Trend magazine. One-hundred companies are ... #7 for 2014, FCCI has been in the top ...
(Date:7/28/2014)... for patients with one of the UK,s most common ... Chronic obstructive pulmonary disease (COPD) is the name for ... to long-term damage to the lungs. Often linked ... of all hospital admissions in the UK, with a ... they are discharged. , A team of ...
(Date:7/28/2014)... 2014 The report “Industrial Enzymes ... & Beverages, Cleaning Agents, Bio-Fuel, Animal Feed), & ... defines and segments the global industrial enzymes market ... for industrial enzymes. It also identifies driving and ... with analysis of trends, opportunities, burning issues, winning ...
Breaking Medicine News(10 mins):Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 2Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4
... Tenn., Nov. 2 Brookdale Senior Living Inc. (NYSE: ... for the third quarter of 2009. , Bill ... results this quarter which build on the success of the ... operating effectively in today,s difficult environment as evidenced by our ...
... FDA NOTE TO CORRESPONDENTS , SILVER SPRING, ... Administration (FDA) today released a listing of eight recent ... products. These updates can be accessed from the agency,s ... You can sign-up for e-mail notices of new ...
... Nov. 2 The Ensign Group, Inc. (Nasdaq: ENSG ... nursing, rehabilitative care services, hospice care and assisted living companies, ... year 2009. , (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ) , ... , Total revenue was a record $132.9 million, up ...
... Highest Levels of BPA Were Detected in Some Samples of Green ... Levels Shown to Cause Harm in Animal Studies; FDA,s Safety Standards ... 2 Consumer Reports, latest tests of canned foods, including ... of the 19 name-brand foods tested contain measurable levels of Bisphenol ...
... patients with HER2 positive tumors one centimeter or smaller are ... those with early-stage disease who do not express the aggressive ... University of Texas M. D. Anderson Cancer Center. The ... Oncology , is the first large study to analyze this ...
... who received influenza vaccine during pregnancy were hospitalized at ... according to preliminary results of an ongoing study by ... the study October 29 at the 47th annual meeting ... Influenza is a major cause of serious ...
Cached Medicine News:Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 2Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 3Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 4Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 5Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 6Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 7Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 8Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 9Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 10Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 11Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 12Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 13Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 14Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 15Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 16Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 17Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 18Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 19Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 20Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 21Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 22Health News:Brookdale Announces Third Quarter 2009 Results; CFFO per Share Increases 43% 23Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 2Health News:FDA CONSUMER HEALTH INFORMATION UPDATES: Fraudulent H1N1 flu products, hearing aids, sound amplifiers, tobacco regulation, FDA's international posts, LASIK eye surgery, and FDA MedWatch safety alerts 3Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 2Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 3Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 4Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 5Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 6Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 7Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 8Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 9Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 10Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 11Health News:The Ensign Group Reports Third Quarter 2009 Adjusted Earnings of $0.38 per Share 12
(Date:7/28/2014)... 28, 2014  Surgical Theater, LLC announced today ... Business Advisory Board. New members include Ori ... Business Development and New Technologies for Given Imaging ... Senior Vice President and General Manager of Philips ... flight simulation technology to brain surgery and has ...
(Date:7/28/2014)... 2014  VigeneTech, Inc, in collaboration with BioLegend, ... Analysis Software, an OEM software solution for analysis ... and offers varieties of bead-based multi-analyte immunoassay products ... of VigeneTech,s data analysis software, FCS data files ... reported LEGENDplex™ software is a ...
(Date:7/28/2014)... July 28, 2014  Array BioPharma Inc. (Nasdaq: ... the fourth quarter and full year of ... to discuss those results on Tuesday, August ... and Michael Carruthers , Chief Financial ... August 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) ...
Breaking Medicine Technology:Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2
... oncology: most, actively researched disease area Researchers ... reagent performance ... Strategic Diagnostics,Inc. (Nasdaq: SDIX ) -- today announced ... reagents in support of oncology-based research and,discovery. These high-quality ...
... FASgen,s fatty acid synthase,inhibitor (FASi) compounds, led ... xenograft cell line tested, in both orthotopic,and flank ... H1975; LX7); two,ovarian; breast; and, colon. In many ... been shown in extensive preclinical studies to,be remarkably ...
Cached Medicine Technology:Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 2Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 3Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 4Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog 5FASgen Announces Significant Milestone in Its Cancer Drug Development Program 2
... Pectoralis Implants come in three styles. ... is by far the most popular style. ... and are packaged and sold individually, not ... that they are each made for a ...
... In vivo results may be affected by the ... scar tissue can impact the desired augment-ation 1 ... from patient to patient. Implant dimensions can be ... surgical scissors. All dimensions in centimeters. This device ...
... in the IQmark family elevates your ECG and ... portability, cost-savings and efficient patient care. The IQmark ... the office, clinics and medical centers as well ... used in conjunction with the IQmark Digital ECG ...
24-hour full disclosure , Input range: 5mV , Analog bandwidth: 0.05 to 100Hz (3dB) , Common mode rejection ratio: 60dB , Dimensions: 4.46in. x 2.75in. x 1.02in. (113mm x 70mm x 26mm) , We...
Medicine Products: